Literature DB >> 11994389

Cosecretion of estrogen and inhibin B by a feminizing adrenocortical adenoma: impact on gonadotropin secretion.

Jean Marc Kuhn1, Hervé Lefebvre, Celine Duparc, Anne Pellerin, Jean Pierre Luton, Georges Strauch.   

Abstract

We describe the first reported case of a feminizing adrenocortical adenoma cosecreting estrogens and inhibin B. A 39-yr-old man, with no previous history of disease and free of treatment, complained of gynecomastia without any clinical abnormality. Plasma E2 and T were 496 pmol/liter and 8.7 nmol/liter, respectively. Testicular echography was normal, and abdominal computed tomography scan showed a 28-mm right adrenal tumor. hCG (5000 IU, im) induced a rise in plasma T levels (20.7 nmol/liter) without any change in plasma E2 levels. Basal plasma LH and FSH levels were undetectable. GnRH (100 microg, i.v.) induced an increase in plasma LH levels without a change in plasma FSH levels. The mean plasma inhibin B level was 330 +/- 45 pg/ml (normal range, 94-327). Pulsatile GnRH administration (20 microg/pulse every 90 min for 3 d) stimulated LH secretion, whereas FSH secretion remained blunted. The patient underwent surgery to remove a 12-g adrenal adenoma. Six months later, plasma E2 and T levels were normalized. LH showed a spontaneous pulsatile pattern, and the mean plasma FSH level was 4.8 U/liter. The secretion of both gonadotropins was stimulated during a pulsatile GnRH administration performed in the same manner as before surgery. The mean plasma inhibin B level was 210 +/- 25 pg/ml. Immunohistochemical studies revealed the presence of aromatase in clusters of tumor cells. Incubation of tumor sections with anti-beta(B)-inhibin antibody revealed intense staining in groups of cells that were also labeled with anti-alpha-inhibin antibody. These data show that the tumor cosecreted E2 and inhibin B, which were both responsible for inhibition of gonadotropin secretion. Tumor secretions appeared to be much more potent in suppressing FSH than LH levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994389     DOI: 10.1210/jcem.87.5.8468

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Subclinical Cushing's syndrome associated with an adrenocortical oncocytoma.

Authors:  S S Lee; K H Baek; Y S Lee; J M Lee; M I Kang; B Y Cha; K W Lee; H Y Son; S K Kang
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

Review 2.  Feminizing adrenocortical tumors: Literature review.

Authors:  Farida Chentli; Ilyes Bekkaye; Said Azzoug
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

3.  Feminizing adrenal tumors: Our experience about three cases.

Authors:  Farida Chentli; Chentli Farida; Ilyes Bekkaye; Bekkaye Ilyes; Smina Yahiaoui; Yahiaoui Smina; Sabrina Souidi; Souidi Sabrina; Nora Soumeya Fedala; Fedala Nora Soumeya; Said Azzoug; Azzoug Said
Journal:  Indian J Endocrinol Metab       Date:  2013-05

4.  Reversal of a Blunted Follicle-Stimulating Hormone by Chemotherapy in an Inhibin B-Secreting Adrenocortical Carcinoma.

Authors:  Stéphanie Espiard; Najiba Lahlou; Mathilde Sibony; Estelle Louiset; Marie Bienvenu; Jérôme Bertherat; Bertrand Dousset; Lionel Groussin; Rossella Libé
Journal:  J Endocr Soc       Date:  2017-01-12

Review 5.  Feminizing Adrenocortical Tumors as a Rare Etiology of Isosexual/Contrasexual Pseudopuberty

Authors:  Doğuş Vurallı; Nazlı Gönç; Alev Özön; Saniye Ekinci; H. Serkan Doğan; Serdar Tekgül; Ayfer Alikaşifoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2021-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.